转移性黑色素瘤患者多数未被纳入关键性III期免疫治疗试验
丹麦全国性转移性黑色素瘤(MM)数据库分析显示,2014年首次肿瘤学评估的276例未选择患者中,55%不符合五项近期随机III期免疫治疗试验的一项或多项入选标准;不符合组中位总生存期5.43个月,符合组18.3个月(P<0.0001,HR 2.44)。
要点
- 55%的转移性黑色素瘤患者不符合III期免疫治疗试验入选标准。
- 体能状态≥2或活动性/未治疗已知脑转移占不符合原因的74%。
- 不符合标准组中位总生存期5.43个月,符合组18.3个月(P<0.0001,HR 2.44)。
核心结论
- 超过半数接受全身治疗的转移性黑色素瘤患者未被纳入III期注册免疫治疗试验。
- 数据揭示新型免疫治疗在真实世界患者群体中有效性的巨大知识缺口,并敦促在选定预后不良队列中进一步测试已知方案。
研究设计与样本
- 丹麦MM数据库包含全国性地理区域内全部未选择的MM人群数据。
- 纳入2014年首次肿瘤学评估的276例未选择MM病例(排除眼黑色素瘤)。
- 分析七项预先定义的入选标准,均用于五项近期随机III期免疫治疗试验的患者筛选。
主要发现
- 55%的MM总人群在首次评估时不符合一项或多项入选标准(「不符合」组)。
- 体能状态≥2或活动性/未治疗已知脑转移单独占不符合原因的74%。
- 「不符合」组中位总生存期5.43个月,符合组18.3个月(P<0.0001,HR 2.44)。
- 接受免疫治疗的患者无论是否符合标准,生存结局相似。
关键数值与推荐
- 七项预先定义的入选标准用于五项近期随机III期免疫治疗试验。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Recent randomised phase III trials have led to the approval of several immune checkpoint inhibitors for unresectable or metastatic melanoma (MM). These trials all employed strict patient selection criteria, and it is currently unknown how large proportion of 'real-world' patients diagnosed with MM is not represented in these trials. PATIENTS AND METHODS: The Danish MM Database contains data on the entire, unselected population of MM within a nationwide geographical area. A total of 276 unselected cases of MM (ocular melanoma excluded), referred for first oncological evaluation in 2014, were included in the analysis. Seven pre-defined eligibility criteria, all used to select patients for enrolment in five recent randomised phase III immunotherapy trials, were analysed. RESULTS: Fifty-five percent of the total population with MM did not meet one or more eligibility criteria ('not eligible' group) at first evaluation. PS ≥ 2 or active/untreated known brain metastases accounted alone for 74% of non-eligibility cases. Median overall survival in the 'not eligible' group was 5.43 months versus 18.3 months for the eligible (p < 0.0001, hazard ratio (HR) 2.44), reflected by significantly worse baseline prognostic features. However, patients treated with immunotherapy had similar survival outcomes regardless of eligibility. CONCLUSION: Over half of the patients evaluated for systemic treatment of MM are not represented in phase III registration immunotherapy trials. The data reveal a huge knowledge gap regarding the usefulness of new immunotherapies in the 'real-world' patient population, and urge additional testing of known regimens in selected poor prognosis cohorts.
引用
- Donia M, Kimper-Karl ML, Høyer KL, et al. The majority of patients with metastatic melanoma are not represented in pivotal phase III immunotherapy trials. Eur J Cancer. 2017. PMID: 28335891. doi:10.1016/j.ejca.2016.12.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。